Global Somatostatin Analogue Drug Market Size, Competitive Analysis, Share, Forecast- 2020-2026

Orion Market Research

Global Somatostatin Analogue Drug Market Size, Competitive Analysis, Share, Forecast- 2020-2026 Request a Free Sample @ https://www.omrglobal.com/request-sample/somatostatinanalogue-drug-market

Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

The global somatostatin analogue drug market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, and new product launches are some of the key factors contributing to the growth of the hormone therapy replacement therapy market across the globe. According to the American Cancer Society, there are around 5,000 new carcinoid tumors diagnosed in the US each year. According to the National Center for Biotechnology Information, 1 million cases of neuroendocrine tumors (NET) occur every year across the globe which is expected to get increased in the future due to the high adoption of sedentary lifestyles. The NET is found to have low incidence and high prevalence, the high prevalence of NET. The rapid diagnosis of the NET disorder enhances the adoption rate of the drugs for the treatment of the disease, thereby promoting the growth of the somatostatin analogue drug market across the globe.

To learn more about this report request a free sample @ https://www.omrglobal.com/request-sample/somatostatin-analogue-drug-market

copy

Camurus AB, Chiasma, Inc., Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Tarveda Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and so on are the prominent players operating in the somatostatin analog drug across the globe. The major players of the somatostatin analogue drug market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are anticipated to make a major contribution to the growth of the somatostatin analogue drug market across the globe.

Browse for Full Report Description@ reports/somatostatin-analogue-drug-market

https://www.omrglobal.com/industry-

Global Somatostatin Analogue Drug Market Segmentation Type   

Octreotide Lanreotide Pasireotide

Indication   

Neuroendocrine Tumor (NET) Acromegaly Others

Global Somatostatin Analogue Drug Market – Segment by Region North America

 

United States Canada

Europe      

UK Germany Italy Spain France Rest of Europe

Asia-Pacific    

China Japan India Rest of the Asia-Pacific

Rest of the World Company Profiles 

Boehringer Ingelheim International GmbH



Camurus AB



Chiasma, Inc.



Dauntless Pharmaceuticals, Inc.



Eli Lilly & Co.



F. Hoffmann-La Roche, Ltd.



Hutchison MediTech, Ltd.



Ipsen Group



Midatech Pharma Plc



Novartis AG



Peptron, Inc



Pfizer, Inc.



Sun Pharmaceutical Industries, Ltd.



Tarveda Therapeutics, Inc.



Teva Pharmaceutical Industries, Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/somatostatin-analogue-drug-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404